Concordia Healthcare to buy PE-backed drugs maker for $1.9 bln: Reuters
Canada's Concordia Healthcare Corp said it would buy Amdipharm Mercury Ltd from European private equity firm Cinven for US$1.9 billion to expand its portfolio of drugs aimed at treating rare diseases, Reuters reported. Including debt, the deal is valued at US$3.3 billion.
8 September 2015•2 mins read
